Cargando…

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

BACKGROUND: The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood. PATIENTS AND METHODS: E1609 enrolled 1673 patients with resected hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarhini, Ahmad A, Kang, Ni, Lee, Sandra J, Hodi, F Stephen, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriet M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108687/ https://www.ncbi.nlm.nih.gov/pubmed/33963015 http://dx.doi.org/10.1136/jitc-2021-002535

Ejemplares similares

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
por: Eljilany, Islam, et al.
Publicado: (2023)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
por: Cmelak, Anthony, et al.
Publicado: (2020)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
por: Villaruz, Liza C., et al.
Publicado: (2015)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial
por: Murphy, Caitlin C., et al.
Publicado: (2021)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Third IRAS Conference
por: Lawrence, Andrew
Publicado: (1988)

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)
por: Ballinger, Tarah J., et al.
Publicado: (2022)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023)

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
por: Schneider, Bryan P, et al.
Publicado: (2015)

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
por: King, Rebecca L., et al.
Publicado: (2018)

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
por: Stein, Mark N., et al.
Publicado: (2019)

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)
por: Bradbury, Angela R., et al.
Publicado: (2021)

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
por: Swinnen, Lode J., et al.
Publicado: (2017)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2022)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2023)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
por: Wagner, Michael J, et al.
Publicado: (2021)

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)
por: Oswald, Laura B., et al.
Publicado: (2020)

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2021)

Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2022)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
por: Kemeny, M. Margaret, et al.
Publicado: (2022)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
por: Moradian, Saeed, et al.
Publicado: (2023)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

The witches' advocate. Basque witchcraft and the Spanish Inquisition (1609–1614)
por: Walker, D. P.
Publicado: (1982)

Complete Genome Sequence of Agrobacterium tumefaciens 1D1609
por: Haryono, Mindia, et al.
Publicado: (2018)

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC
por: Varlotto, John M., et al.
Publicado: (2022)

Ira
por: Petsko, Gregory A
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_76quu95d6ekjsv0ipmui87pm04